Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT03989349 · COMPLETED

Trial details

NCT number: NCT03989349
Sponsor: Galderma R&D
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Moderate-to-Severe Atopic Dermatitis

Start date: 2019-06-30
Primary completion: 2022-02-23
Enrollment: 787

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.